Fecal transplants show promise in improving melanoma treatment
In a world-first clinical trial published in the journal Nature Medicine, a multi-centre study from Lawson Health Research Institute, the Centre hospitalier de l'Université de Montréal (CHUM) and the Jewish General Hospital (JGH) has found fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma. (Source: World Pharma News)
Source: World Pharma News - July 7, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Episode 4: Immunotoxicity and Metastatic Breast Cancer Episode 4: Immunotoxicity and Metastatic Breast Cancer
Drs Banu Arun and Hope S. Rugo discuss immunotherapy, immunotoxicity, and comorbidities among diverse patient populations in advanced and metastatic breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
A Promising Immunotherapy Against Small Cell Lung Cancer A Promising Immunotherapy Against Small Cell Lung Cancer
This editorial provides commentary on the results from a study investigating the potential of a promising new targeted therapy for small cell lung cancer.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
SNMMI: Experts debate AI's role in nuclear medicine
CHICAGO - AI applications in nuclear medicine are beginning to pick up stea...Read more on AuntMinnie.comRelated Reading:
AI model estimates mortality risk on SPECT heart exams
AI developed for PET/CT lung cancer imaging
PET/CT predicts survival in women with inflammatory breast cancer
AI may help diagnose cardiac amyloidosis on whole-body scintigraphy
PET/CT radiomics could help select patients for immunotherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 27, 2023 Category: Radiology Source Type: news
FDA approves Roche ’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed period of time,Columvi provides patients with a treatment end date and potential time off treatmentColumvi is part of Roche ' s industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approvedLunsumioto treat follicular lymphomaBasel, 16 June 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Source: Roche Media News - June 27, 2023 Category: Pharmaceuticals Source Type: news
Key Data in Endometrial Cancer From ASCO 2023 Key Data in Endometrial Cancer From ASCO 2023
Top abstracts in endometrial cancer from ASCO 2023 include patient-reported outcomes in the RUBY trial, genetic testing referral rates, and the impact of MMR deficiency on immunotherapy responses.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
Combo Therapy Could Treat Oral Melanomas in Dogs
TUESDAY, June 27, 2023 -- Could a treatment combo that improves the odds against melanoma for humans work in dogs?
Yes, claims a new study that found radiotherapy followed by immunotherapy extended survival in canine melanoma patients.
Melanomas in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 27, 2023 Category: General Medicine Source Type: news
Neoadjuvant Immunotherapy for CRC: Too Good to Be True? Neoadjuvant Immunotherapy for CRC: Too Good to Be True?
Breakthrough findings on the effectiveness of neoadjuvant immunotherapy could help usher in a new treatment paradigm for colorectal cancer.Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Phase 3 Keytruda, Chemotherapy Mesothelioma Trial Shows Promising Results
Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural mesothelioma, according to the latest results of a phase 3 clinical trial.
The results were announced in June at the annual meeting of the American Society of Clinical Oncology. They showed Merck’s use of the anti-PD-1 treatment combined with chemotherapy reduced the patient’s risk of death by 21%.
Clinical trial results of the multimodal treatment using immunotherapy and chemo also showed a median overall survival of 17.3 months in comparison...
Source: Asbestos and Mesothelioma News - June 26, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Scientists Say They ’ve Reached Turning Point in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine.
After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years.
These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer.
More from TIME
[video id=W5jcvwLu autostart="viewable"]
“We’re getting something to work. Now we need to get...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news
Scientists Say They ’ve Reached ‘Turning Point’ in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine.
After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years.
These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer.
“We’re getting something to work. Now we need to get it to work better,” said Dr. James Gulley, who help...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news
SNMMI: New theranostics pair shows promise in pancreatic cancer
CHICAGO - A new theranostics imaging and treatment approach shows promise i...Read more on AuntMinnie.comRelated Reading:
PET/MRI emerges as a valuable theranostics technology
UCLA Health to open new theranostics center
SNMMI highlights prostate cancer study
In 2023 and beyond, AI is redefining radiology
PET/CT predicts survival outcomes in immunotherapy patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2023 Category: Radiology Source Type: news
Magdeburg researchers discover a new mechanism of cancer immune defense
Modern immunotherapies boost the body's own defenses against cancer. They activate killer T cells of the immune system that can specifically recognize and destroy cancer cells. In many patients, however, cancer cells adapt and become invisible to killer T cells so that the treatment is no longer effective. An interdisciplinary team of researchers from Magdeburg has now discovered a new mechanism that enables the immune system to also eliminate such invisible cancer cells. (Source: World Pharma News)
Source: World Pharma News - June 23, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Roundup: South Korean AI software for sepsis detection gets US FDA nod and more briefs
Also, South Korean researchers have built an AI model for predicting the side effects of immunotherapy on a patient. (Source: mobihealthnews)
Source: mobihealthnews - June 23, 2023 Category: Information Technology Source Type: news
Study hints at how cancer immunotherapy can be safer
New research can help scientists predict, treat, or even prevent side effects of immunotherapies that rely on disabling protective proteins in healthy tissues. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 21, 2023 Category: Universities & Medical Training Source Type: news
